Earnings ·
Amgen Inc. reported second quarter 2026 financial results on August 4, 2026
AMGNAmgen Inc
Amgen Inc. reported second quarter 2026 financial results on August 4, 2026. Total revenues increased 10% to $10.1 billion, driven by a 9% rise in product sales. GAAP earnings per share rose 65% to $4.37, while non-GAAP EPS increased 4% to $6.29. The company generated $3.5 billion in free cash flow and declared a quarterly dividend of $2.52 per share, paid on June 5, 2026, representing a 6% increase from the prior year. Full-year 2026 guidance projects total revenues between $38.2 billion and $39.4 billion and non-GAAP EPS between $22.30 and $23.50. Amgen Inc. operates in the biotechnology industry, discovering, developing, manufacturing, and delivering innovative medicines to treat cancer, heart disease, inflammatory conditions, rare diseases, and obesity.